Alkem Laboratories Limited — PPTs, 29-05-2025: Investor Presentation

1. Financial Highlights:

Alkem Laboratories posted Q4 revenue of ₹3,144 Cr, up 7.1% YoY, led by 8.1% growth in India (₹2,136 Cr) and 7.2% growth internationally (₹975 Cr). EBITDA was ₹391 Cr with a 12.4% margin, down from 13.7%, reflecting margin pressure. Net profit rose 4.2% to ₹306 Cr. FY25 revenue increased 2.3% YoY to ₹12,964 Cr, supported by 6.5% growth in India, though international sales were down 4.5%. EBITDA margin improved to 19.4% from 17.7%, with EBITDA growing 11.9% to ₹2,512 Cr. Net profit surged 20.6% to ₹2,166 Cr. Cash and cash equivalents remained strong at ₹4,620 Cr.

2. Strategic Initiatives & Growth Drivers:

Robust domestic momentum came from gastrointestinal, VMN, respiratory, and gynecology segments. R&D investment stayed healthy at ~5% of revenue in Q4 and 4.3% for FY25, supporting pipeline expansion. The focus on non-US international markets like Australia and Europe resulted in solid growth, while the US business faced challenges despite active ANDA filings and approvals.

3. Business Developments:

In Q4, 6 ANDA filings and 4 approvals were secured for the US market; FY25 totaled 9 filings and 14 approvals (including tentative). Non-US markets achieved double-digit growth, driven by Australia and Europe. Domestic market share gains were seen in anti-diabetic, respiratory, and urology therapies.

4. Market Position & Competitive Advantage:

Alkem ranks 5th in Indian pharma with strongholds in anti-infectives, gastrointestinal, pain management, and supplements. A diversified portfolio across acute and chronic therapies and geographic presence spanning India, US, Latin America, Australia, and Asia mitigate risks. Robust manufacturing capabilities and successful regulatory inspections enhance supply consistency and quality.

5. Investor Implications:

Consistent domestic growth, margin expansion, and solid R&D signal positive growth potential. International opportunities remain, but US market softness poses execution risks to watch. Pipeline progress and expanding global reach offer improved growth visibility. Strong cash flow and rising profitability underpin financial stability and shareholder value upside.